Abstract
Relevance. Medicinal products of plant origin have long been successfully used in the treatment of various diseases, including those of viral etiology. Nevertheless, their effect on the replication of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has not been studied so far. Objective. To evaluate the potential of drugs based on validated plant extracts – RE (Bronchipret, Bronchipret TP, Tonsilgon N, Sinupret extract, Tonsipret) with respect to their ability to suppress SARS-CoV-2 replication in vitro. Materials and methods. Vero cells (Vero) incubated with RE of different concentrations were infected with SARS-CoV-2 virus. After 48 h the virus replication (the number of viral RNA copies in cell culture supernatant) was determined by quantitative polymerase chain reaction. Results. SARS-CoV-2 RNA copy number under the action of non-cytotoxic concentrations of Bronchipret TP decreased by 1000 times and by 10 times under the action of drugs Tonsilgon N and Tonsipret. Conclusion. Some of the studied REs in vitro demonstrated promising antiviral activity. It is advisable to conduct further, including clinical, studies of their activity against SARS-CoV-2 in the treatment of coronavirus infection (COronaVirus Disease 2019 – COVID-19).
Highlights
В работах, посвященных исследованию терапевтического потенциала лекарственных растений, встречаются и данные об их многообещающей противовирусной активности [7], способностях влиять на различные стадии репликации вируса и/или стимулировать процессы регенерации, модулировать иммунный ответ организма-хозяина
To evaluate the potential of drugs based on validated plant extracts – RE (Bronchipret, Bronchipret TP, Tonsilgon N, Sinupret extract, Tonsipret) with respect to their ability to suppress SARS-CoV-2 replication in vitro
Vero cells (Vero) incubated with RE of different concentrations were infected with SARS-CoV-2 virus
Summary
Исследование потенциала препаратов на основе экстрактов лекарственных растений в отношении подавления репликации SARS-CoV-2: пилотное исследование*. Микела Луиза Де Пеллегрин, Анетт Рорхофер, Филипп Шустер, Барбара Шмидт, Филипп Петербурс*3, Андре Гесснер. Оценить потенциал препаратов на основе валидированных растительных экстрактов – РЭ (Бронхипрет, Бронхипрет ТП, Тонзилгон Н, Синупрет экстракт, Тонзипрет) в отношении их способности к подавлению репликации SARS-CoV-2 in vitro. Количество копий РНК SARS-CoV-2 под действием нецитотоксических концентраций препарата Бронхипрет ТП снизилось в 1 тыс. Целесообразно проведение дальнейших, в том числе клинических, исследований их активности в отношении SARS-CoV-2 при лечении коронавирусной инфекции (COronaVirus Disease 2019 – COVID-19). Ключевые слова: SARS-CoV-2, COVID-19, репликация вируса, растительные препараты, Бронхипрет, Бронхипрет ТП, Тонзилгон Н, Синупрет экстракт, Тонзипрет Для цитирования: Де Пеллегрин М.Л., Рорхофер А., Шустер Ф., Шмидт Б., Петербурс Ф., Гесснер А.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
